Alvotech Guides FY26 Revenue to $650M-$700M, Above Consensus
ALVO sits 39% above its 52-week low of $2.94.
Summary
Alvotech issued FY26 revenue guidance of $650M-$700M, a range that implies significant growth from current levels and likely exceeds analyst expectations. The company has been actively raising capital and advancing biosimilar approvals, so this forward view provides a concrete financial target. The guidance comes after a $165M capital raise in June and a new $75M term loan in July, suggesting management is confident in scaling commercialization. Investors will focus on whether the range is achievable given recent FDA interactions and manufacturing inspection outcomes.
At the time of this announcement, ALVO was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $2.94 to $9.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.